Short Interest in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Declines By 38.7%

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the recipient of a large drop in short interest in February. As of February 28th, there was short interest totalling 14,600 shares, a drop of 38.7% from the February 13th total of 23,800 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average trading volume of 473,200 shares, the days-to-cover ratio is presently 0.0 days.

60 Degrees Pharmaceuticals Trading Up 8.0 %

Shares of NASDAQ SXTP opened at $1.89 on Monday. The firm has a market capitalization of $2.78 million, a PE ratio of -0.19 and a beta of 4.52. 60 Degrees Pharmaceuticals has a 1 year low of $1.41 and a 1 year high of $35.99. The firm’s 50-day moving average is $3.26 and its 200-day moving average is $4.95.

Analyst Ratings Changes

Several brokerages have recently issued reports on SXTP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, March 7th. HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Tuesday, February 25th.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.